Europe Cancer Immunotherapy Market Size to register a growth of 13.5% CAGR

20-11-2018 | Report Format: Electronic (PDF)

Growth, Trends and Report Highlights

According to a new report Europe Cancer Immunotherapy Market, published by KBV research, the Europe Cancer Immunotherapy Market would witness market growth of 13.5% CAGR during the forecast period (2018 – 2024).

The Germany market would dominate the Europe Monoclonal Antibodies Cancer Immunotherapy Market by 2024; growing at a CAGR of 12.4 % during the forecast period. The UK market is expected to witness a CAGR of 13% during (2018 - 2024). Additionally, The France market is expected to witness a CAGR of 15.5% during (2018 - 2024).

The Hospitals market dominated the Europe Cancer Immunotherapy Market by End User 2017, thereby, achieving a market value of $20828.1 million by 2024, growing at a CAGR of 13.6 % during the forecast period. The Clinics market is expected to witness a CAGR of 13.2% during (2018 - 2024). Additionally, The Other End User market is expected to witness highest CAGR of 13.8% during (2018 - 2024).

The Lung Cancer market dominated the Russia Cancer Immunotherapy Market by Application 2017, growing at a CAGR of 12.8 % during the forecast period. The Melanoma market is expected to witness a CAGR of 15.8% during (2018 - 2024). Additionally, The Head & Neck Cancer market is expected to witness highest CAGR of 14.7% during (2018 - 2024).

Full Report: https://www.kbvresearch.com/europe-cancer-immunotherapy-market/

The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the mentioned countries. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of AstraZeneca, Amgen Inc., Eli Lilly and Company, Merck & Co., Inc., Bristol-Myers Squibb Company, Pfizer Inc., Bayer Ag, Immunomedics Inc., Novartis AG, F. Hoffmann-La Roche Ltd